CRISPR-Cas13 system and use thereof
US12297450B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 27, 2024 |
| Grant date | May 13, 2025 |
| Priority date | — |
| Expiry date | Jun 27, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/531
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to a CRISPR-Cas13 system and use thereof, and also relates to a Cas13 protein, a fusion protein, and a guide polynucleotide. The Cas13 protein has at least 90% sequence identity compared to SEQ ID NO: 1. The fusion protein comprises the Cas13 protein fused to a protein domain and/or a polypeptide tag. The guide polynucleotide comprises a same-direction repetition sequence and a guide sequence that has been engineered to hybridize with the target RNA. The same-direction repetition sequence has at least 70% sequence identity to any of SEQ ID NOs: 3 and 80-87. The CRISPR-Cas13 system comprises the Cas13 protein that has at least 90% sequence identity to SEQ ID NO: 1, or a coding nucleic acid therefor, and the guide polynucleotide or a coding nucleic acid therefor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.